A multi-cancer test panel that simultaneously screens for multiple cancers from a single
|
|
Aristotle® is a multi-cancer test panel that uses mRNA technology to detect multiple cancer signatures from a single sample of blood. Aristotle has been built on our proprietary mRNA technology platform, The Sentinel Principle®, which has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Aristotle needs to be prescribed by a physician and is available through AVRT™, StageZero's comprehensive telehealth program that uses advanced diagnostics and physician supervision to help patients detect cancer in the earliest stages.
|
For Employers & Organizations
|
Sensitivity and Specificity
ARISTOTLE has been demonstrated to identify sets of gene transcripts capable of classifying subjects as having a specific cancer with a high degree of sensitivity and specificity.
Sources:
1) Aristotle: A single blood test for pan-cancer screening.Adam A Dempsey, Samuel Chao, Dimitri Stamatiou, Tanya Pilcz, Jay Ying, and Robert Burakoff; Journal of Clinical Oncology 2020 38:15_suppl, e15037-e15037
1) Aristotle: A single blood test for pan-cancer screening.Adam A Dempsey, Samuel Chao, Dimitri Stamatiou, Tanya Pilcz, Jay Ying, and Robert Burakoff; Journal of Clinical Oncology 2020 38:15_suppl, e15037-e15037
Aristotle® was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes. The Aristotle™ test must be ordered by and used only in consultation with a healthcare provider.
